Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in WDC?
WideCells Group: THE INVESTMENT CASE

WideCells establishes 'end-to-end' stem cell service

Mission is to make stem cell treatments accessible and affordable to as many people as possible
laboratory
INVESTMENT OVERVIEW: WDC The Big Picture
“The group is now positioned to focus on revenue generation from all three of our divisions," said Joao Andrade, chief executive officer of the company

Stem cells are one of the hottest areas of medical research in the hope (and expectation) that one day they will help treat many diseases.

Certain ailments such as bone marrow transplants already use them a standard treatment but cost and access remain barriers.

That is where WideCells Group PLC (LON:WDC) enters the picture.

WATCH: WideCells secures deal with international stem cell storage giant

Its mission is to make stem cell treatments accessible and affordable to as many people as possible through an ‘end-to-end’ service.

Currently the group has three arms

CellPlan is a stem cell healthcare insurance plan that makes stem cell transplants affordable for families who require treatment for life-threatening diseases.

WideCells Group Science focuses on stem cell research and stem cell storage.

Wideacademy, launched in February 2018, is the education and training division and provides free-to-access educational areas with paid for premium digital tools and resources for doctors/medical professionals.

“The group is now positioned to focus on revenue generation from all three of our divisions," said Joao Andrade, chief executive officer of the company.

Licence from the UK’s Human Tissue Authority

WideCells took a “significant step” towards its end-to-end ambition with the grant of a licence by the UK’s Human Tissue Authority.

This allows the company to import, export, process, store and distribute for treatment umbilical cord blood and tissue.

Umbilical cord cells are one main sources of a person’s stem cells and storing them following the birth of a child for use later on is a rapidly growing business.

Getting a UK licence enabled the group, under its brand name BabyCells, to offer umbilical cord blood and tissue storage services to clients in the UK and Europe.

UK Knowledge Transfer Partnership with Manchester Metropolitan University

In March, WideCells was granted a government-backed Innovate UK Knowledge Transfer Partnership with Manchester Metropolitan University to undertake research on a new form of stem cell technology.

The new technology allows specialised adult cells such as skin, to be genetically reprogrammed to assume a stem cell-like state and accordingly be used in treatment and in the study of disease.

Following the three-year research project, WideCells hopes to have these advanced induced pluripotent stem cells (iPSCs) to a point of commercialisation so that the technology can be included in the group’s end-to-end stem cell service offering.

Expanding into Asian market

WideCells has also signed a deal to bring stem cell insurance product, CellPlan, to the Asian market.

The agreement had been signed with Cryoviva, a cord blood storage facility with operations in Thailand, Singapore, and India.

Cryoviva to date had almost 250,000 inspected samples stored, with forecasts to store around 25,000 new samples per year going forward.

WideCells added that product will be launched to Cryoviva customers on a phased basis, commencing in the second half of 2018, and would provide staged revenue increases. 

The agreement will be another step in geographical expansion for the group, following recent contracts in both Europe and South America.

Early days

WideCells results so far have reflected its early stage status. In the six months to 30 June 2017, loss before tax was £880,000 on nominal sales.

The market value of £7mln at 10.7p also highlights that the group currently is just at the start of its development.

View full WDC profile View Profile

WideCells Group Timeline

Related Articles

scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use